P S Anderson

Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors.

E A Emini, P. Anderson, P. Darke, 1991, Journal of medicinal chemistry.

Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.

S Diamond, S S Ko, G L Trainor, 2000, Journal of medicinal chemistry.

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

B. E. Evans, D. Veber, K. Rittle, 1988, Journal of medicinal chemistry.

Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.

P. Anderson, J. Thies, W. J. Thompson, 1990, Journal of medicinal chemistry.

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

P. Anderson, W. Schleif, E. Emini, 1995, Antimicrobial agents and chemotherapy.

Structure-based design of HIV-1 protease inhibitors: replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran.

P. Anderson, J. Huff, P. Fitzgerald, 1994, Journal of medicinal chemistry.

Dopamine receptors labelled by PHNO

R D Larsen, P. Anderson, P. Seeman, 1993, Synapse.

Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma.

J J Baldwin, M. Murcko, P. Anderson, 1989, Journal of medicinal chemistry.

Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.

B. E. Evans, D. Veber, K. Rittle, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260.

B. E. Evans, K. Rittle, M. Bock, 1989, Journal of medicinal chemistry.